ASH 2023 preview – the first cell therapy winners
Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.
Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.
Meanwhile, Bristol Myers Squibb hands back two mystery projects.
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.
Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.
But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.
But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.